ResMed (RMD) Stock Forecast & Price Target

$249.99 +0.43 (+0.17%)

(As of 05:54 PM ET)

ResMed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
1

Hold
5

Buy
6

Based on 12 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 5 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$225.70
-9.72% Downside

According to the 12 analysts' twelve-month price targets for ResMed, the average price target is $225.70. The highest price target for RMD is $283.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted downside of -9.72% from the current price of $249.99.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	9 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$225.70	$220.55	$204.70	$202.33
Forecasted Upside	-9.72% Downside	-13.87% Downside	-15.65% Downside	32.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-9.72% Downside	25,212.72% Upside	6.71% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/25/2024	KeyCorp 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$251.00 ➝ $266.00	+3.55%
10/25/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$224.00 ➝ $232.00	-9.68%
10/25/2024	Needham & Company LLC 3 of 5 stars	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
❗[Investor Alert] Under-the-Radar Tech (Ad) While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO Click here for all the details about today's open round of investing.
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/27/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$215.00	+9.88%
1/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$175.00 ➝ $180.00	-3.41%
1/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$160.00 ➝ $195.00	+7.32%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$180.00 ➝ $169.00	+21.82%
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%
1/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kaczor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:40 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 22, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. has recently declared a quarterly dividend of $0.53, which translates to an annualized dividend of $2.12 and a yield of 0.84%. This consistent dividend payment can provide a steady income stream for investors.
The company is expected to post an EPS of 9.22 for the current year, indicating strong earnings potential and growth prospects, which can attract investors looking for profitable opportunities.
Recent analyst ratings show a positive outlook, with several brokerages upgrading their ratings and price targets, including a "buy" rating from StockNews.com and a target price increase from Bank of America to $270.00, suggesting confidence in the company's future performance.
Institutional investors and hedge funds own 54.98% of ResMed Inc.'s stock, indicating strong institutional confidence and support, which can be a positive signal for retail investors.
The current stock price is approximately $248.38, reflecting a solid valuation in the market, which may present a good entry point for potential investors.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Despite the positive outlook, Wolfe Research has maintained an "underperform" rating on ResMed Inc., indicating potential concerns about the stock's performance relative to the market.
Insider selling has been observed, with executives selling shares worth over $14 million in the last ninety days, which could signal a lack of confidence in the stock's short-term performance.
The company's payout ratio is 28.08%, which, while sustainable, may limit the potential for future dividend increases, potentially disappointing income-focused investors.
Market volatility and economic uncertainties could impact the healthcare sector, including ResMed Inc., making it a riskier investment in the current climate.
With a moderate buy rating from analysts, there may be limited upside potential compared to other investment opportunities, which could deter some investors seeking higher returns.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $225.70, with a high forecast of $283.00 and a low forecast of $180.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 5 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RMD shares.
: According to analysts, ResMed's stock has a predicted downside of -9.72% based on their 12-month stock forecasts.
: Over the previous 90 days, ResMed's stock had 1 upgrade and 1 downgrade by analysts.
: ResMed has been rated by research analysts at Baird R W, Bank of America, KeyCorp, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Wolfe Research in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

This page (NYSE:RMD) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target